Grant of Interim Extension of the Term of U.S. Patent No. 6,100,082; OCSTM, 44391 [2017-20272]

Download as PDF Federal Register / Vol. 82, No. 183 / Friday, September 22, 2017 / Notices returning the halibut to the water without further delay. All stages of the sampling process with the exception of (e), above, would be conducted by a member of the fishing vessel’s crew. Viability assignments would be conducted by the NMFStrained fishery observer on the vessel. The sampling process is expected to require less than 2 minutes and have no impact on the probability of survival of the sampled fish. The sampling protocol outlined above is quicker and less obtrusive than any of the protocols used by the IPHC for halibut tag-and-release that have been shown to yield excellent survival of the handled individuals. Halibut is a prohibited species in the groundfish fishery, requiring immediate return to the sea with a minimum of injury. This proposed action would exempt the participating vessel from the requirement to return all prohibited species, or parts thereof, to the sea immediately, with a minimum of injury, regardless of its condition at § 679.21(b)(2)(ii). Under the EFP, the participating vessel would be limited to its groundfish allocations under the 2018 harvest specifications. No additional target or prohibited species catch (PSC) amounts beyond those authorized through regulation would be needed for this EFP; all groundfish catch will accrue against the Pacific cod sector’s catch and PSC allowances. EFPauthorized fishing activities would not be expected to change the nature or duration of the Pacific cod hook-andline fishery or the amount or species of fish caught by the participating vessel. In 2018, the IPHC would be required to submit to NMFS a report of the EFP results after EFP experimental fishing has ended in 2018. The report would include: The number of halibut sampled and their recorded lengths. The fieldwork that would be conducted under this EFP is not expected to have a significant impact on the human environment as detailed in the categorical exclusion prepared for this action (see ADDRESSES). In accordance with § 679.6, NMFS has determined that the application warrants further consideration and has forwarded the application to the Council to initiate consultation. The Council is scheduled to consider the EFP application during its October 2017 meeting, which will be held in Anchorage, AK. The EFP application will also be provided to the Council’s Scientific and Statistical Committee for review at the October Council meeting. The applicant has been invited to appear in support of the application. VerDate Sep<11>2014 18:11 Sep 21, 2017 Jkt 241001 Public Comments Interested persons may comment on the application at the October 2017 Council meeting during public testimony or until October 10, 2017. Information regarding the meeting is available at the Council’s Web site at http://www.npfmc.org. Copies of the application and categorical exclusion are available for review from NMFS (see ADDRESSES). Comments also may be submitted directly to NMFS (see ADDRESSES) by the end of the comment period (see DATES). Authority: 16 U.S.C. 1801 et seq. Dated: September 18, 2017. Emily H. Menashes, Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 2017–20186 Filed 9–21–17; 8:45 am] BILLING CODE 3510–22–P DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. PTO–P–2017–0038] Grant of Interim Extension of the Term of U.S. Patent No. 6,100,082; OCSTM Lung System United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. AGENCY: The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 6,100,082. FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to her attention at (571) 273–7755; or by email to Mary.Till@uspto.gov. SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On September 6, 2017, TransMedics, Inc, an exclusive licensee of the patent owner of record, the Department of Veterans Affairs, timely filed an SUMMARY: PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 44391 application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 6,100,082. The patent claims the medical device product, the OCS Lung System. The application for patent term extension indicates that a Premarket Approval Application (PMA) P160013 was submitted to the Food and Drug Administration (FDA) on April 28, 2016. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the original expiration date of the patent, September 23, 2017, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 6,100,082 is granted for a period of one year from the original expiration date of the patent. Dated: September 14, 2017. Robert Bahr, Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office. [FR Doc. 2017–20272 Filed 9–21–17; 8:45 am] BILLING CODE 3510–16–P COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED Procurement List; Proposed Additions and Deletions Committee for Purchase From People Who Are Blind or Severely Disabled. ACTION: Proposed addition to and deletions from the Procurement List. AGENCY: The Committee is proposing to add a service to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and deletes products and services previously furnished by such agencies. DATES: Comments must be received on or before October 22, 2017. ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, 1401 S. Clark Street, Suite 715, Arlington, Virginia 22202–4149. FOR FURTHER INFORMATION CONTACT: For further information or to submit comments contact: Amy B. Jensen, Telephone: (703) 603–7740, Fax: (703) SUMMARY: E:\FR\FM\22SEN1.SGM 22SEN1

Agencies

[Federal Register Volume 82, Number 183 (Friday, September 22, 2017)]
[Notices]
[Page 44391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20272]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2017-0038]


Grant of Interim Extension of the Term of U.S. Patent No. 
6,100,082; OCSTM Lung System

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting a one-year interim extension of the term of U.S. Patent 
No. 6,100,082.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On September 6, 2017, TransMedics, Inc, an exclusive licensee of 
the patent owner of record, the Department of Veterans Affairs, timely 
filed an application under 35 U.S.C. 156(d)(5) for an interim extension 
of the term of U.S. Patent No. 6,100,082. The patent claims the medical 
device product, the OCS Lung System. The application for patent term 
extension indicates that a Premarket Approval Application (PMA) P160013 
was submitted to the Food and Drug Administration (FDA) on April 28, 
2016.
    Review of the patent term extension application indicates that, 
except for permission to market or use the product commercially, the 
subject patent would be eligible for an extension of the patent term 
under 35 U.S.C. 156, and that the patent should be extended for one 
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory 
review period will continue beyond the original expiration date of the 
patent, September 23, 2017, interim extension of the patent term under 
35 U.S.C. 156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 6,100,082 is granted for a period of one year from the 
original expiration date of the patent.

    Dated: September 14, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2017-20272 Filed 9-21-17; 8:45 am]
 BILLING CODE 3510-16-P